Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/43847
Title: In vitro synergistic interaction between DTA0100 and radiation in human cancercell lines
Authors: Bordón Rodríguez, Elisa de los Reyes 
León, Leticia G.
Ríos-Luci, Carla
Lara, Pedro C.
Padrón, José M.
UNESCO Clasification: 32 Ciencias médicas
Keywords: Anticancer drugs
Antiproliferative
Cancer
Catalytic inhibitor
Cell lines, et al
Issue Date: 2012
Publisher: 1871-5206
Journal: Anti-Cancer Agents in Medicinal Chemistry 
Abstract: DTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.
URI: http://hdl.handle.net/10553/43847
ISSN: 1871-5206
DOI: 10.2174/187152012802650057
Source: Anti-Cancer Agents in Medicinal Chemistry [ISSN 1871-5206], v. 12, p. 988-993
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

2
checked on Apr 21, 2024

Page view(s)

48
checked on Jul 22, 2023

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.